Pharmaceutical US pharma giant Merck & Co says its investigational 15-valent pneumococcal conjugate vaccine,V114, has received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients six weeks to 18 years of age. 31 January 2019